Financing round-up: AWAK Technologies, Canton Biologics, AbolerIS Pharma, EverImmune

France: EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, has secured €3.46m (US$3.7m) in funding from Bpifrance, under the ‘Innovation in biotherapeutics’ scheme. Proceeds enable the company to conduct a phase I/II clinical trial for its drug candidate Oncobax AK in patients undergoing immunotherapy. This funding,…

You must be a HMI Subscriber to view this content.

Subscribe Now »